Drug · DIN 02498235
SARCLISA
FOR I.V. INFUSION. SINGLE-USE VIALS
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 3, 2020; first marketed July 3, 2020.
- Drug Identification Number (DIN)
- 02498235
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Isatuximab L01FC02
- Class
- Human
- Record last updated
- August 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ISATUXIMAB | 100 MG | 5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 29, 2020: NOC 23530New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “sarclisa”. A notice may cover another product or only some lots: read it to see what it covers.
- Limited number of Sarclisa single use vials may have been frozen during shipmentSeptember 25, 2026 · Biologic or vaccine · Product quality · Type I
Other DINs named SARCLISA
- DIN 02498243 · Marketed